— Data, Models and Insights —
Data Syndication and IP
Koneksa’s syndicated data licensing model offers immediate access to rigorously collected digital and clinical measures from studies conducted under full GCP oversight. Use these datasets to drive internal decision-making, enhance clinical trial design, and generate real-world evidence - all at a fraction of the cost of traditional research.
Why License Syndicated Data?
Start Ahead,
Not From Scratch
Jumpstart R&D efforts with early access to high-quality datasets collected through Koneksa-led studies. Get insights into biomarker trends, participant subgroups, and exploratory endpoints before public dissemination - no new trial required.
Inform and De-Risk Clinical Strategy
Leverage external data to refine biomarker selection, optimize inclusion/exclusion criteria, and simulate endpoints. Syndicated data supports better-informed trial design, and provides teams with hands-on experience using digital measures to inform their clinical development strategy.
Fuel Reverse Translation and Disease Modeling
Bridge preclinical and clinical research with integrated datasets that combine traditional measures and novel digital endpoints. Syndicated data can support mechanism-of-action studies, model disease progression, and strengthen translational frameworks.
Generate Evidence for
Regulatory and Scientific Engagement
Syndicated datasets are designed for scientific and regulatory decision-making, with perpetual license rights that may include raw data access, analytic outputs, and commercialization references. Use this data to support publications, abstracts, and payer or regulatory submissions.
KH007: A Case Study
in Syndicated Data Value
KH007 is a syndicated, pre-competitive study led by Koneksa to validate digital biomarkers in Parkinson’s disease
Active assessments completed to date
ePROs and eDiaries completed to date
Hours of wearable data captured to date
0
0
0
Change in Progression:
in-clinic MDS-UPDRS evaluations completed to date
Cognitive Assessments:
in-clinic digital cognitive tasks completed to date
Vital Signs:
in-clinic vital signs assessments completed to date
0
0
Study Deliverables
Data Available to Members of KH007 Syndication
Koneksa Platform
Continuous access via the Koneksa platform
Updated in real time
Participant enrollment and attributes
Assessment completion and wrist wearable adherence
Configurable data visualizations
Digital Assessments
Digital data
transfers
Monthly data, with periodic daily data
Active assessment results
ePRO & eDiary responses
Passive measures
In-Clinic Data
Interim and final transfers
Data transferred after site visits
Change in progression
Cognitive Assessments
Vital signs
Participant Characteristics
Interim and final transfers
Data available, updated as needed
Medical & disease history
Concomitant medications
Demographics
Study Highlights
-
Prospective, multicenter disease progression study
-
Fully enrolled n=82 in under 11 months
-
Interim analysis underway with ~90% adherence to digital data capture
-
Healthy control cohort in development
-
Cumulative study data available in real-time
-
Full dataset available by mid-2026
11
Fully Enrolled n=82
< 11 Months
Adherence to Digital Data Capture
~90%
1.5
3
-
Estimated
Years Saved
$8-10M
Estimated
Savings in Millions
Syndication Benefits
-
Real-time access to all data throughout the study
-
Participation in collaborative analyses and publications
-
Cost- and time-efficient alternative to independent study launch
-
Estimated savings: $8–10M and 1.5–3 years
-
Pathway to regulatory acceptance of digital endpoints
Why it Matters
KH007 demonstrates how syndicated data can provide deep scientific and operational value - faster and more cost-effectively than running a new study. As a syndication partner, you gain early insights, collaborative engagement opportunities, and a strategic edge in Parkinson’s drug development.
A Smarter, Faster Way to Generate Clinical Insight
Licensing syndicated data gives your team a meaningful head start -whether you're exploring new biomarkers, modeling disease progression, or preparing for regulatory engagement. Koneksa’s studies are designed for utility across industry, with transparency, quality, and licensing flexibility at their core.
